Comparison

PHA-793887 European Partner

Item no. S1487-10000
Manufacturer Selleckchem
CASRN 718630-59-2
Amount 10 g
Quantity options 10 mg 1 g 10 g 10 mM/1 ml 200 mg 5 mg 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CC(C)CC(=O)NC1=NNC2=C1CN(C2(C)C)C(=O)C3CCN(CC3)C
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias 718630-59-2'
Similar products PHA-793887
Available
Manufacturer - Targets
CDK7, CDK5, CDK2
Storage Conditions
2 years -80 in solvent
Molecular Weight
361, 48
Administration
Intravenous injection once daily
Animal Models
Mouse xenograft models of human ovarian A2780, colon HCT-116 and pancreatic BX-PC3 carcinoma
Cell lines
A2780 cells
Clinical Trials
A Phase I clinical trial of PHA-793887 for advanced/metastatic solid tumors has been terminated.
Concentrations
0.1 nM-1 uM, dissolved in DMSO
Dosages
10, 20, and 30 mg/kg
Formulation
Dissolved in 5% dextrose solution
IC50
8 nM, 8 nM, 8 nM, 8 nM, 8 nM, 8 nM
In vitro
[1]
In vivo
PHA-793887 (10–30 mg/kg) shows good efficacy in the human ovarian A2780, colon HCT-116, and pancreatic BX-PC3 carcinoma xenograft models. [1] PHA-793887 (20 mg/kg) is effective in xenograft models of K562 and HL60 cells, primary leukemic disseminated model, and a high-burden disseminated ALL-2 model derived from a relapsed Philadelphia-positive acute lymphoid leukemia patient. [2]
Incubation Time
72 hours
Kinase Assay
[3], CDK Kinase Assay, The biochemical activity of compounds is determined by incubation with specific enzymes and substrates, followed by quantitation of the phosphorylated product. PHA-793887 (1.5 nM–10 uM) is incubated for 30 90 min at room temperature in the presence of ATP/33P-gamma-ATP mix, substrate, and the specific enzyme (0.7 100 nM) in a final volume of 30 uL of kinase buffer, using 96 U bottom plates. After incubation, the reaction is stopped and the phosphorylated substrate is separated from nonincorporated radioactive ATP using SPA beads, Dowex resin, or Multiscreen phosphocellulose filter as follows: (1) For SPA Assays. The reaction is stopped by the addition of 100 uL of PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 uM ATP, containing 1 mg of streptavidin-coated SPA beads. After 20 min of incubation for substrate capture, 100 uL of the reaction mixture is transferred into Optiplate 96-well plates containing 100 uL of 5 M CsCl, left to stand for 4 hours to allow stratification of beads to the p of the plate, and counted using TopCount to measure substrate-incorporated phosphate. (2) For Dowex Resin Assay. An amount of 150 uL of resin/formate, pH 3.00, is added to stop the reaction and capture unreacted 33P-gamma-ATP, separating it from the phosphorylated substrate in solution. After 60 min of rest, 50 uL of supernatant is transferred to Optiplate 96-well plates. After the additon of 150 uL of Microscint 40, the radioactivity is counted in the TopCount. (3) For Multiscreen Assay. The reaction is stopped with the addition of 10 uL of EDTA (150 mM). An amount of 100 uL is transferred to a MultiScreen plate to allow substrate binding to phosphocellulose filter. Plates are then washed three times with 100 uL of H2PO4 (75 mM) filtered by a MultiScreen filtration system, and dried. After the additon of 100 uL of Microscint 0, radioactivity is counted in the TopCount. IC50 values are obtained by nonlinear regression analysis.
Method
Cells are seeded into 96- or 384-wells plates at final concentration ranging from 1x104 to 3x104 per cm2. After 24 hours, cells are treated using serial dilution of PHA-793887. At 72 hours after the treatment, the amount of cells are evaluated using the CellTiter-Glo assay. IC50 values are calculated using a sygmoidal fitting.
Solubility (25C)
DMSO 72 mg/mL, Water <1 mg/mL, Ethanol 72 mg/mL
Information
PHA-793887 is a novel and potent inhibitor of CDK2, CDK5 and CDK7 with IC50 of 8 nM, 5 nM and 10 nM. It is greater than 6-fold more selective for CDK2, 5, and 7 than CDK1, 4, and 9. PHA-793887 induces cell-cycle arrest and apoptosis. Phase 1.
Chemical Name
N-(6, 6-dimethyl-5-(1-methylpiperidine-4-carbonyl)-1, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazol-3-yl)-3-methylbutanamide
Features
Multi-CDKs inhibitor.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 g
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?